Photo taken from Vivek Subbiah/LinkedIn
Aug 11, 2023, 17:44
Vivek Subbiah: Pleased to share our back-to-back papers unveiling promising results of Lurbinectedin
Hot off the press Pleased to share our back-to-back papers unveiling promising results of Lurbinectedin.
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial & exploratory translational study.
We report the activity & safety analysis of lurbinectedin monotherapy in addition to a translational exploratory analysis of endometrial molecular subtypes showing better PFS and OS in the TP53 wild-type, low/absent p53 protein immunohistochemical (IHC) and No Specific Molecular Profile (NSMP) molecular subgroups OncoAlert.
For the article: click here
Source: Vivek Subbiah / Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 24, 2024, 13:29
Dec 24, 2024, 12:28
Dec 24, 2024, 12:16
Dec 24, 2024, 12:09
Dec 24, 2024, 11:44